NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
25021-0416-01 | 25021-0416 | Plerixafor | Plerixafor | 20.0 mg/mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Aug 1, 2024 | In Use | |
25021-0259-51 | 25021-0259 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug 1, 2024 | In Use | |
25021-0259-50 | 25021-0259 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug 1, 2024 | In Use | |
25021-0258-61 | 25021-0258 | Melphalan Hydrochloride | Melphalan Hydrochloride | 50.0 mg/10ml | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Apr 1, 2024 | In Use | |
25021-0255-50 | 25021-0255 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb 1, 2024 | In Use | |
25021-0255-05 | 25021-0255 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb 1, 2024 | In Use | |
25021-0255-17 | 25021-0255 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb 1, 2024 | In Use | |
25021-0254-16 | 25021-0254 | Docetaxel Anhydrous | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 1, 2023 | In Use | |
25021-0254-08 | 25021-0254 | Docetaxel Anhydrous | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 1, 2023 | In Use | |
25021-0253-51 | 25021-0253 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jul 1, 2023 | In Use | |
25021-0253-50 | 25021-0253 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jul 1, 2023 | In Use | |
25021-0252-51 | 25021-0252 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Jun 15, 2023 | In Use | |
25021-0251-50 | 25021-0251 | Mitomycin | Mitomycin | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Jun 15, 2023 | In Use | |
25021-0250-20 | 25021-0250 | Mitomycin | Mitomycin | 5.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Jun 15, 2023 | In Use | |
25021-0249-51 | 25021-0249 | Cyclophosphamide | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jan 15, 2024 | In Use | |
25021-0248-51 | 25021-0248 | Cyclophosphamide | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jan 15, 2024 | In Use | |
25021-0246-02 | 25021-0246 | Thiotepa | Thiotepa | 15.0 mg/1.5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intracavitary, Intravenous, Intravesical | Jun 15, 2018 | In Use | |
25021-0245-04 | 25021-0245 | Docetaxel Anhydrous | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 15, 2017 | In Use | |
25021-0245-01 | 25021-0245 | Docetaxel Anhydrous | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 15, 2017 | In Use | |
25021-0244-10 | 25021-0244 | BORTEZOMIB | BORTEZOMIB | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 1, 2022 | In Use | |
25021-0242-02 | 25021-0242 | Fludarabine phosphate | Fludarabine phosphate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Oct 15, 2016 | In Use | |
25021-0241-10 | 25021-0241 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | May 15, 2017 | In Use | |
25021-0239-05 | 25021-0239 | gemcitabine | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan 15, 2019 | Sep 30, 2020 | No Longer Used |
25021-0239-52 | 25021-0239 | gemcitabine | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan 15, 2019 | Aug 31, 2020 | No Longer Used |
25021-0239-26 | 25021-0239 | gemcitabine | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan 15, 2019 | Feb 28, 2021 | No Longer Used |
Found 11120 results — Export these results